Aquestive Therapeutics, Inc. (AQST)
Largest Insider Buys in Sector
AQST Stock Price History Chart
AQST Stock Performance
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with …
Insider Activity of Aquestive Therapeutics, Inc.
Over the last 12 months, insiders at Aquestive Therapeutics, Inc. have bought $0 and sold $429,685 worth of Aquestive Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aquestive Therapeutics, Inc. have bought $54,873 and sold $951,234 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $4,050 was made by Boyd Peter E. (SVP‑Bus. Process & Info. Tech.) on 2022‑06‑14.
List of Insider Buy and Sell Transactions, Aquestive Therapeutics, Inc.
| 2024-03-15 | Sale | Chief Innovation/Tech Officer | 50,000 0.0672% | $6.00 | $300,000 | -33.17% | ||
| 2024-03-08 | Sale | Chief Innovation/Tech Officer | 25,000 0.0364% | $5.19 | $129,685 | -16.09% | ||
| 2022-06-14 | SVP-Bus. Process & Info. Tech. | 5,000 0.0107% | $0.81 | $4,050 | +11.38% | |||
| 2022-06-08 | Chief Innovation/Tech Officer | 45,871 0.1074% | $0.96 | $44,036 | +2.88% | |||
| 2022-06-08 | SVP-Bus. Process & Info. Tech. | 2,293 0.0054% | $0.96 | $2,201 | +2.88% | |||
| 2022-06-08 | General Counsel | 13,761 0.0322% | $0.96 | $13,211 | +2.88% | |||
| 2021-02-10 | Sale | 23,460 0.0662% | $6.75 | $158,355 | -38.78% | |||
| 2021-02-09 | Sale | 11,540 0.0328% | $6.75 | $77,895 | -38.02% | |||
| 2021-02-08 | Sale | 40,792 0.1131% | $6.50 | $265,148 | -37.03% | |||
| 2020-08-18 | Sale | 3,000 0.0088% | $8.00 | $24,000 | -37.84% | |||
| 2020-06-04 | Sale | 100,000 0.2958% | $5.11 | $510,620 | +2.92% | |||
| 2020-05-08 | Sale | 80,000 0.2312% | $5.00 | $400,000 | +3.69% | |||
| 2020-04-29 | Sale | 80,000 0.2256% | $4.50 | $360,000 | +12.42% | |||
| 2020-04-27 | Sale | 80,000 0.229% | $4.00 | $320,000 | +28.37% | |||
| 2020-04-14 | Sale | 80,000 0.2445% | $3.85 | $308,000 | +42.40% | |||
| 2020-03-16 | 4,000 0.0058% | $0.75 | $3,000 | +246.43% | ||||
| 2020-03-16 | 28,000 0.0837% | $1.54 | $43,249 | +246.43% | ||||
| 2019-08-27 | 4,000 0.0166% | $3.99 | $15,960 | +14.36% | ||||
| 2019-08-21 | 1,800 0.0068% | $3.81 | $6,858 | +7.92% | ||||
| 2019-08-20 | 22,620 0.0909% | $3.80 | $86,001 | +15.08% |
Insider Historical Profitability
| Schobel Alexander Mark | Chief Innovation/Tech Officer | 984476 1.0811% | $5.11 | 4 | 9 | <0.0001% |
| Kendall Keith J | 638964 0.7017% | $5.11 | 6 | 1 | <0.0001% | |
| BRATTON DOUGLAS K | 165000 0.1812% | $5.11 | 1 | 0 | ||
| Maxwell John T. | 150614 0.1654% | $5.11 | 2 | 1 | <0.0001% | |
| Barber Daniel | 101959 0.112% | $5.11 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| Bratton Capital Management L P | $41.79M | 10.78 | 9.81M | 0% | +$0 | 100 | |
| Vr Adviser Llc | $23.67M | 6.1 | 5.56M | New | +$23.67M | 1.15 | |
| The Vanguard Group | $13.81M | 3.56 | 3.24M | +71.65% | +$5.77M | <0.0001 | |
| Franklin Templeton Investments | $9.46M | 2.44 | 2.22M | New | +$9.46M | <0.01 | |
| Laurion Capital Management LP | $6.58M | 1.7 | 1.55M | New | +$6.58M | 0.05 |